Dieses Forum nutzt Cookies
Dieses Forum verwendet Cookies, um deine Login-Informationen zu speichern, wenn du registriert bist, und deinen letzten Besuch, wenn du es nicht bist. Cookies sind kleine Textdokumente, die auf deinem Computer gespeichert sind; Die von diesem Forum gesetzten Cookies düfen nur auf dieser Website verwendet werden und stellen kein Sicherheitsrisiko dar. Cookies auf diesem Forum speichern auch die spezifischen Themen, die du gelesen hast und wann du zum letzten Mal gelesen hast. Bitte bestätige, ob du diese Cookies akzeptierst oder ablehnst.

Ein Cookie wird in deinem Browser unabhängig von der Wahl gespeichert, um zu verhindern, dass dir diese Frage erneut gestellt wird. Du kannst deine Cookie-Einstellungen jederzeit über den Link in der Fußzeile ändern.

Illumina
WKN:ILMN
#1
Notiz 

Illumina

Illumina Earnings miss, Revenue beats In Q4

The firm reported earnings per share of $1.32 on revenue of $867M. Analysts polled by Investing.com anticipated EPS of $1.36 on revenue of $862.29M. That compared to EPS of $1.44 on revenue of $714.0M in the same period a year earlier. The company had reported EPS of $1.52 on revenue of $853M in the previous quarter.

Illumina shares lost 0.93% to trade at $282.60 in after-hours trade following the report.

...

https://finance.yahoo.com/news/illumina-...03919.html

[Bild: ILMNc1dl0522.png]
#2
Notiz 

RE: Illumina

Why Illumina Stock Is Tanking Today

What happened
Shares of Illumina (NASDAQ: ILMN) were tanking today, down 16% as of 10:27 a.m. EDT, after the genomic sequencing leader announced preliminary results for its second quarter on Thursday evening. Illumina said that it expects to report Q2 revenue of $835 million -- $50 million lower than what Wall Street analysts anticipated.

The company also updated its full-year 2019 guidance. Illumina now projects revenue growth of around 6%, less than half its previous forecast of full-year revenue growth between 13% and 14%.


...

https://finance.yahoo.com/news/why-illum...50465.html

[Bild: ILMNc1dl1343.png]

__________________
#3
Notiz 

RE: Illumina

Illumina (ILMN) Beats Q3 Earnings Estimates, Raises View

Illumina, Inc.’s ILMN third-quarter 2019 adjusted earnings per share (EPS) of $1.93 surpassed the Zacks Consensus Estimate by 37.9%. Moreover, the bottom line improved 26.9% from the year-ago quarter’s figure.

Including one-time items, the company reported EPS of $1.58, up 18.8% year over year.

Revenues

In the quarter under review, Illumina’s revenues rose 6.3% year over year to $907 million. The top line also surpassed the Zacks Consensus Estimate by 4%. The year-over-year growth can be attributed to the company’s collaborations to develop distributable clinical IVDs for Illumina sequencers.


...

https://finance.yahoo.com/news/illumina-...01269.html

[Bild: ILMNc1dl1533.png]

__________________
#4
Notiz 

RE: Illumina

Illumina (ILMN) Q4 Earnings and Revenues Top Estimates

Illumina (ILMN) came out with quarterly earnings of $1.70 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.32 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 6.92%. A quarter ago, it was expected that this genetic testing tools company would post earnings of $1.40 per share when it actually produced earnings of $1.93, delivering a surprise of 37.86%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Illumina, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $953 million for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 0.63%. This compares to year-ago revenues of $867 million.


...

https://finance.yahoo.com/news/illumina-...10863.html

[Bild: ILMNc1dl1613.png]

__________________
#5
Notiz 

RE: Illumina

       

https://www.insidermonkey.com/blog/river...ad-971077/


Gehe zu:


Benutzer, die gerade dieses Thema anschauen: 1 Gast/Gäste